While tech waffles on going public, biotech IPOs boom

For people who make investment decisions based on revenues and projected earnings, biotech IPOs are kind of a non-starter. Not only are new market entrants universally unprofitable, most have zero revenue. Going public is mostly a means to raise money for clinical trials, with red ink expected for years to come. That pattern may be one reason the venture capital press,Crunchbase Newsincluded, tends to devote a disproportionately small portion of coverage to biotech IPOs. Learn more about your ad choices. Visit podcastchoices.com/adchoices